Question to the Department for Education:

To ask the Secretary of State for Education, if she will make an assessment of the potential impact of ADHD medication shortages on children in school.

The Department of Health and Social Care (DHSC) has been working hard with industry and NHS England to help resolve the supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are affecting the United Kingdom and other countries around the world. As a result of intensive work, some issues have been resolved and all strengths of lisdexamfetamine, atomoxetine capsules, and guanfacine prolonged-release tablets are now available.

The DHSC are intensively working to resolve issues with methylphenidate prolonged-release tablets by collaborating with current suppliers to resolve issues as soon as possible, expanding the UK supplier base with new suppliers, and partnering with NHS England to improve demand forecasting for ADHD medicines.

The DHSC is also supporting an independent cross-sector taskforce that NHS England has established to look at ADHD service provision and support across sectors and their impact on patient experience. The taskforce is bringing together expertise from across a broad range of sectors, including the NHS, education and justice to better understand the challenges affecting people with ADHD, including timely access to services and support. The ADHD taskforce will also work closely with the Department for Education’s neurodivergence task and finish group.